5-(4-苯氧基苯基)戊酸乙酯 | 100596-53-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-(4-苯氧基苯基)戊酸乙酯
• 英文名称: Ethyl 5-(4-phenoxyphenyl)pentanoate
• CAS: 100596-53-0
• 化学式: C₁₉H₂₂O₃
• 分子量: 298.382
• InChiKey: LMNNFEKMWMBZBE-UHFFFAOYSA-N

物化性质

• 沸点：
  404.1±38.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(4-苯氧基苯基)戊酸乙酯 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 5-(4-苯氧基苯基)戊酸
  参考文献：
  名称：

  NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 Protein

  摘要：

  The E2 protein is required far the replication of human papillomaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas, Using an NMR-based screen, we tested compounds for binding to the DNA-binding domain of the HPV-E2 protein. Three classes of compounds were identified which bound to two distinct sites on the protein. Biphenyl and biphenyl ether compounds containing a carboxylic acid bind to a site near the DNA recognition helix and inhibit the binding of E2 to DNA. Benzophenone-containing compounds which lack a carboxylic acid group bind to the beta-barrel formed by the dimer intel face and exhibit negligible effects on the binding of E2 to DNA. Structure-activity relationships from the biphenyl and biphenyl ether compounds were combined to produce a compound [5-(3'-(3 '',5 ''-dichlorophenoxy)phenyl)-2,4-pentadienoic acid] with an IC50 value of approximately 10 mu M. This compound represents a useful lead for the development of antiviral agents that interfere with HPV replication and further illustrates the usefulness of the SAR by NMR method in the drug discovery process.

  DOI：

  10.1021/jm9703404
• 作为产物：
  描述：

  4-苯氧基苯甲醛 在 palladium on activated charcoal lithium hexamethyldisilazane 作用下， 以 乙醇 为溶剂， 反应 6.5h， 生成 5-(4-苯氧基苯基)戊酸乙酯
  参考文献：
  名称：

  NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 Protein

  摘要：

  The E2 protein is required far the replication of human papillomaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas, Using an NMR-based screen, we tested compounds for binding to the DNA-binding domain of the HPV-E2 protein. Three classes of compounds were identified which bound to two distinct sites on the protein. Biphenyl and biphenyl ether compounds containing a carboxylic acid bind to a site near the DNA recognition helix and inhibit the binding of E2 to DNA. Benzophenone-containing compounds which lack a carboxylic acid group bind to the beta-barrel formed by the dimer intel face and exhibit negligible effects on the binding of E2 to DNA. Structure-activity relationships from the biphenyl and biphenyl ether compounds were combined to produce a compound [5-(3'-(3 '',5 ''-dichlorophenoxy)phenyl)-2,4-pentadienoic acid] with an IC50 value of approximately 10 mu M. This compound represents a useful lead for the development of antiviral agents that interfere with HPV replication and further illustrates the usefulness of the SAR by NMR method in the drug discovery process.

  DOI：

  10.1021/jm9703404

文献信息

• ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS
  申请人：Oldfield Eric

  公开号：US20120022024A1

  公开（公告）日：2012-01-26

  This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.

  本公开涉及包括用于抑制、预防和/或治疗微生物感染的组合物和方法，包括对金黄色葡萄球菌等病原体引起的感染。
• PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：TAISHO PHARMACEUTICAL CO., LTD

  公开号：US20150175541A1

  公开（公告）日：2015-06-25

  There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I′): (in the above-mentioned general formula (I′), W, Y, R 2 , R 3 , R 4 , and Y 4 are as described hereinabove), or pharmaceutically acceptable salts thereof.

  提供了一些化合物，具有优越的PHD2抑制作用，其通式表示为(I'):(在上述通式(I')中，W、Y、R2、R3、R4和Y4如上所述)，或其药学上可接受的盐。
• Inhibition of Staphyloxanthin Virulence Factor Biosynthesis in <i>Staphylococcus aureus</i>: In Vitro, in Vivo, and Crystallographic Results
  作者：Yongcheng Song、Chia-I Liu、Fu-Yang Lin、Joo Hwan No、Mary Hensler、Yi-Liang Liu、Wen-Yih Jeng、Jennifer Low、George Y. Liu、Victor Nizet、Andrew H.-J. Wang、Eric Oldfield

  DOI：10.1021/jm9001764

  日期：2009.7.9

  The gold color of Staphylococcus aureus is derived from the carotenoid staphyloxanthin, a virulence factor for the organism. Here, we report the synthesis and activity of a broad variety of staphyloxanthin biosynthesis inhibitors that inhibit the first committed step in its biosynthesis, condensation of two farnesyl diphosphate (FPP) molecules to dehydrosqualene, catalyzed by the enzyme dehydrosqualene synthase (CrtM). The most active compounds are phosphonoacetamides that have low nanomolar K-i values for CrtM inhibition and are active in whole bacterial cells and in mice, where they inhibit S. aureus disease progression. We also report the X-ray crystallographic structure of the most active compound, N-3-(3-phenoxyphenyl)propylphosphonoacetamide (IC50 = 8 nM, in cells), bound to CrtM. The structure exhibits a complex network of hydrogen bonds between the polar headgroup and the protein, while the 3-phenoxyphenyl side chain is located in a hydrophobic pocket previously reported to bind farnesyl thiodiphosphate (FsPP), as well as biphenyl phosphonosulfonate inhibitors. Given the good enzymatic, whole cell, and in vivo pharmacologic activities, these results should help guide the further development of novel antivirulence factor-based therapies for S. aureus infections.
• US9422240B2
  申请人：——

  公开号：US9422240B2

  公开（公告）日：2016-08-23
• [EN] ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS<br/>[FR] COMPOSITIONS ANTI-BACTÉRIENNES ET PROCÉDÉS COMPRENANT LE CIBLAGE DE FACTEURS DE VIRULENCE DE STAPHYLOCOCCUS AUREUS
  申请人：UNIV ILLINOIS

  公开号：WO2010123599A9

  公开（公告）日：2011-02-17

  [EN] This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.
  [FR] L'invention se rapporte à des compositions et à des procédés notamment pour l'inhibition, la prévention, et/ou le traitement d'infections microbiennes, y compris des infections par des agents pathogènes tels que Staphylococcus aureus.